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Background: A novel class of transcripts, long non-coding RNAs (lncRNAs), has recently emerged as a key player in
several biological processes, and important roles for these molecules have been reported in a number of complex
human diseases, such as autoimmune diseases, neurological disorders, and various cancers. However, the aberrant
lncRNAs implicated in myasthenia gravis (MG) remain unknown. The aim of the present study was to explore the
abnormal expression of lncRNAs in peripheral blood mononuclear cells (PBMCs) and examine mRNA regulatory
relationship networks among MG patients with or without thymoma.
Methods: Microarray assays were performed, and the outstanding differences between lncRNAs or mRNA
expression were verified through RT-PCR. The lncRNAs functions were annotated for the target genes using Gene
Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway. The potential
regulatory relationships between the lncRNAs and target genes were analyzed using the ‘cis’ and ‘trans’ model.
Outstanding lncRNAs were organized to generate a TF-lncRNA-gene network using Cytoscape software.
Results: The lncRNA and mRNA expression profile analysis revealed subsets of differentially expressed genes in
MG patients with or without thymoma. A total of 12 outstanding dysregulated expression lncRNAs, such as
lncRNA oebiotech_11933, were verified through real-time PCR. Several GO terms including the cellular response
to interferon-γ, platelet degranulation, chemokine receptor binding and cytokine interactions were very important
in MG pathogenesis. The chromosome locations of some lncRNAs and associated co-expression genes were
demonstrated using ‘cis’ analysis. The results of the ‘trans’ analysis revealed that some TFs (i.e., CTCF, TAF1and
MYC) regulate lncRNA and gene expression. The outstanding lncRNAs in each group were implicated in the
regulation of the TF-lncRNA-target gene network.
Conclusion: The results of the present study provide a perspective on lncRNA expression in MG. We identify a
subset of aberrant lncRNAs and mRNAs as potential biomarkers for the diagnosis of MG. The GO and KEGG
pathway analysis provides an annotation to determine the functions of these lncRNAs. The results of the ‘cis’
and ‘trans’ analyses provide information concerning the modular regulation of lncRNAs.
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Myasthenia gravis (MG) is a T and B cell-mediated
autoimmune disease of the neuromuscular junction; cy-
tokines and chemokines may play a crucial role in the
pathogenesis and perpetuation of this disease [1-3].
Muscle weakness and fatigue, as hallmarks of MG, indi-
cate improper signaling between T and B cells, resulting in
the elicitation of an antibody-mediated autoimmune re-
sponse against the acetylcholine receptor (AChR) located
at neuromuscular junctions [4,5]. In most cases, autoanti-
bodies against the AChR are detected. Recently, other
targets, such as muscle-specific kinase (MuSK) and
lipoprotein-related protein 4 (LRP4), have been described
[3]. However, the mechanisms that contribute to the
development or pathogenesis of MG are highly com-
plex. A puzzling yet interesting characteristic of MG is
that many patients show thymic abnormalities, such as
thymic germinal center hyperplasia, whereas other
patients develop thymic tumors [6-9]. The thymus has
long been considered to be closely associated with the
pathogenesis of MG, and some studies have suggested
that MG autoimmune reactions originate in the thymus
[7,10]. The relationship between MG and thymoma has
been repeatedly suggested; however, many questions
and controversies still remain. The biological and clinical
behavior of thymomatous MG following thymectomy has
not been adequately investigated, and evidence is lacking
concerning both the clinical course of MG and the progno-
sis of thymomas associated with MG following surgical
management [7,11]. Therefore, additional studies concern-
ing the role of the thymus gland in the pathogenesis of MG
are required.
Long non-coding RNAs (lncRNAs) are a group of
RNA transcripts that are more than 200 nucleotides in
length and lack significant open reading frames (ORFs)
[12-15]. lncRNAs have only been recently identified, and
most of the functions of these molecules remain unclear.
The long nucleotide chain of lncRNAs can either form a
complex spatial structure that interacts with protein
factors or provide a large region for the concurrent
binding of many molecules that collectively participate in
genomic imprinting, X-chromosome silencing, chromo-
some modification, intranuclear transport, and tran-
scriptional activation and interference [13,14,16-18],
thereby regulating cell growth, differentiation, develop-
ment, senescence and death [19-21]. Although several
lncRNAs molecules have been implicated in diverse
processes and diseases [22,23], only a few examples of
the regulation of the immune system through lncRNAs
have been described [24-26].
In the present study, we performed an array of
lncRNA chip assays on PBMCs of MG patients. The out-
standing lncRNAs functions were annotated based on
co-expression genes and the GO biological process. Therelationships among the lncRNAs were revealed through
‘cis’ and ‘trans’ analyses. These results provide informa-
tion for further studies on MG.
Results
lncRNA and mRNA expression profile in MG
To investigate the expression levels of lncRNAs associated
with MG with or without thymoma, lncRNA and mRNA
microarray analyses were performed on the PBMCs of MG
patients. After separating the signal from noise and
performing a t-test, significant differences in lncRNAs
and mRNA expression of up to two-fold (P < 0.05 and
FDR < 0.05) were observed. These results are summa-
rized in Table 1, and detailed information is provided
in Additional file 1. The lncRNA and mRNA expression
data were clustered using Cluster3.0, as shown in Figure 1.
Using dendrogram-based methods for clustering, the sam-
ples were further separated into two subgroups through
hierarchical clustering based on similar expression pat-
terns, and the results indicate that the expression of
these lncRNAs and mRNAs was significantly different
in MG patients with or without thymoma. This differ-
ence could potentially distinguish the disease group
from MG patients without thymoma or healthy individ-
uals. We also calculated the common upregulation or
downregulation of lncRNA or mRNA expression in
MG patients with or without thymoma versus healthy
controls. A total of 42 lncRNAs exhibited upregulated
expression, and 93 lncRNAs exhibited downregulated
expression (Figure 1D), whereas 80 mRNAs exhibited up-
regulated expression and 43 mRNAs exhibited downregu-
lated expression in the two groups (Figure 1E). The
detailed data are provided in Additional file 2. These re-
sults suggest that these lncRNAs and mRNAs may have
common functions in the development of MG.The lncRNA function annotation and statistical
characteristics network
To further explore the function of lncRNAs in MG, the
results of the lncRNA and mRNA chip analyses were
subjected to Pearson’s correlation coefficient analysis,
in which co-expression was considered at P > 0.8. To
determine the level of lncRNA and mRNA co-
expression, we divided the different lncRNAs into two
subsets: the upregulated lncRNAs and downregulated
lncRNAs. When the subset contained more than 100
different lncRNAs, we selected the top 100 most distin-
guished lncRNAs, and when the subset contained less
than 100 lncRNAs, all lncRNAs in the subset were
used. Because the file is extremely large, the informa-
tion pertaining to lncRNA oebiotech_11933 is shown
as a representative result. The results for the other
lncRNAs are provided in Additional file 3.
Table 1 Dysregulated lncRNAs and mRNAs
mRNA Long non-coding RNA
Experimental group Control group Up-regulated Down-regulated In total Up-regulated Down-regulated In total
MG1-4* N1-4 249 613 862 218 1271 1489
MG5-8 N1-4 263 90 353 172 170 342
MG1-4 MG5-8 59 145 204 52 229 281
MG1-4 represents the MG with thymoma group, MG5-8 represents the MG without thymoma group, and N1-4 represents the healthy control group.
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lation of lncRNA expression among MG patients with
thymoma versus healthy controls. A total of 552 genes
(e.g., G0S2) relative to lncRNA oebiotech_11933 exhibited
P > 90% (Table 2). These genes were further analyzed
using DAVID functional annotation software (http://david.
abcc.ncifcrf.gov/ gene2gene.jsp). The lncRNA oebio-
tech_11933 function was annotated using GO and KEGG
pathway analyses. Selecting the reliability prediction terms
(according to the P-value and enrichment), a total of 20
enrichment GO terms were obtained. Table 3 indicates
that lncRNA oebiotech_11933 was associated with tran-
scriptional regulation, cell surface receptor-linked signal
transduction, and immune responses, among other terms.
Moreover, lncRNA oebiotech_11933 KEGG pathways
are listed in Table 4, including ‘cytokine-cytokine receptor
interaction’, ‘MAPK signaling pathway’, ‘chemokine signal-
ing pathway’, ‘NOD-like receptor signaling pathway’, and
‘Toll-like receptor signaling pathway’. Previous studies
have reported that these pathways are associated with
lymphocyte immune cell proliferation and cancer develop-
ment pathways [27-30]. The results of the GO and KEGG
pathway analyses consistently showed that lncRNA oebio-
tech_11933 is associated with lymphocyte immune cell
proliferation and cancer development pathways.
Furthermore, the lncRNA co-expression genes in each
group were also analyzed using DAVID functional annota-
tion software. The results of the GO and KEGG pathway
analyses for lncRNA oebiotech_11933 are presented. In
addition, the aberrant lncRNA genes were subjected to
GO and KEGG pathway analyses. We selected the top 100
and 200 reliability prediction terms(according to the
P-value and enrichment) for co-expressed and aberrant
lncRNA genes, respectively (Figure 2). In MG patients
with thymoma versus healthy controls, the top 100 terms
in the GO and KEGG pathway analyses were associated
with ‘cellular response to interferon-γ’, ‘positive regulation
of cytokine production’, ‘smooth muscle cell proliferation’,
and ‘cytokine receptors’, among other terms (Figure 2A).
The top 200 terms in the GO and KEGG pathway analyses
were associated with cellular responses to interferon-γ
(Figure 2B). The 7 most common GO terms are shown in
Figures 2A and 2B. The terms ‘cellular response to
interferon-γ’, ‘chemokine receptor binding’ and ‘positive
regulation of cytokine production’ were the most enrichedGO terms. In MG patients without thymoma versus
healthy controls, GOCC platelet alpha granule and GOMF
chemokine receptor binding were the most enriched
among the top 200 GO terms. A total of 14 common GO
terms are shown in the Figures 2C and 2D. ‘chemokine re-
ceptor binding’, ‘cytokine-cytokine receptor interaction’,
and ‘platelet alpha granule’ were the most enriched GO
terms. In the MG with thymoma group versus the MG
without thymoma group, ‘chemokine receptor binding’
and ‘cytokine-cytokine receptor interaction’ were the most
enriched among the top 200 GO terms. A total of 13 com-
mon GO terms are shown in Figures 2E and 2F. ‘chemo-
kine receptor binding’ and ‘cytokine-cytokine receptor
interaction’ were the most enriched GO terms. The results
of the GO and KEGG pathway analyses confirmed that
lncRNAs play important roles in the lymphocyte immune
system, such as inflammation, cell differentiation and
proliferation.
Validation of disturbed lncRNA expression
To verify the disruption of lncRNA expression in MG
patients, real-time PCR was performed to examine the
up-or downregulation of lncRNAs in each group. As
shown in Figures 3A-3D, differences in the expression of
4 lncRNAs were detected in MG patients with thymoma
compared with healthy controls: lncRNA oebiotech_11933
was the most elevated (19.96-fold higher expression),
followed by lncRNA A_24_P927716 (14.75-fold higher ex-
pression), whereas lncRNA A_21_P0010030 and lncRNA
A_21_P0002844 exhibited 3.94- and 6.43-fold lower ex-
pression, respectively. Figures 3E-3H show the differ-
ences in the expression of 4 other lncRNAs in MG
patients without thymoma compared with healthy con-
trols. Figures 3I-3L showthe differences in the expression
of 4 other lncRNAs in the MG with thymoma group com-
pared with the MG without thymoma group. These results
were consistent with the results obtained from the micro-
array chip analysis.
‘Cis’ analysis of the expression of lncRNAs and adjacent
co-expression genes
Evidence suggests that several lncRNAs regulate their
own transcription in ‘cis’, as well as that of nearby genes,
by recruiting remodeling factors to local chromatin [31].
Therefore, we identified the chromosomal co-expression
Figure 1 The differences in cluster heat maps of lncRNA for the three groups. A: The lncRNA and mRNA cluster heatmaps of MG patients
with thymoma compared with healthy controls. B: The lncRNA and mRNA cluster heat map of MG patients without thymoma compared with
healthy controls. C: The lncRNA and mRNA cluster heat map of MG patients with thymoma compared with MG patients without thymoma.
D: Common differentially expressed lncRNAs between MG patients with or without thymoma. The number of common upregulated lncRNAs is
shown on the left, and the number of common downregulated lncRNAs is shown on the right. E: Common differentially expressed mRNAs
between MG patients with or without thymoma. The number of common upregulated mRNAs is shown on the left, and the number of common
downregulated mRNAs is shown on the right. MG1-4 represents the MG with thymoma group, MG5-8 represents the MG without thymoma
group, and N1-4 represents the healthy control group.
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entially expressed lncRNAs to determine potential
lncRNA ‘cis’ genes. We searched the genes in the
chromosome 300 kbp upstream and downstream of the
differentially expressed lncRNAs and identified the com-
mon lncRNA co-expression genes within these regionsof the chromosome; these genes were considered poten-
tial ‘cis’ genes of the lncRNAs. A data reduction strategy
was used to overlay the genes located upstream or
downstream lncRNAs and co-expression genes. The re-
sults of the ‘cis’ analyses were shown in Additional file 4.
In MG patients with thymoma versus healthy controls,
Table 2 Co-expressed genes of lncRNA oebiotech_11933
(only P > 90% genes are shown)
Correlation P-value Gene ID Probe Gene symbol
0.98291 1.12E-08 50486 A_23_P74609 G0S2
0.945413 3.48E-06 2069 A_23_P41344 EREG
-0.94353 4.11E-06 10605 A_23_P207811 PAIP1
0.942434 4.52E-06 23710 A_24_P4816 GABARAPL1
0.93273 9.68E-06 1647 A_23_P23221 GADD45A
0.926358 1.51E-05 64651 A_23_P121011 CSRNP1
-0.9236 1.8E-05 80851 A_33_P3413305 SH3BP5L
0.92047 2.19E-05 64092 A_23_P29005 SAMSN1
0.913331 3.32E-05 64651 A_33_P3224070 CSRNP1
0.912667 3.45E-05 10123 A_33_P3323722 ARL4C
0.911543 3.67E-05 1844 A_24_P37409 DUSP2
0.909644 4.07E-05 124935 A_24_P296508 SLC43A2
0.901592 6.15E-05 392288 A_24_P58037 LOC392288
0.900089 6.62E-05 5142 A_23_P74278 PDE4B
Table 4 KEGG pathway analysis of lncRNA
oebiotech_11933 co-expression genes
Term Count % P-value
hsa04060:Cytokine-cytokine receptor interaction 20 0.47 2.58E-04
hsa04010:MAPK signaling pathway 15 0.35 0.02771
hsa04062:Chemokine signaling pathway 14 0.33 0.003659
hsa04621:NOD-like receptor signaling pathway 9 0.21 4.56E-04
hsa04620:Toll-like receptor signaling pathway 7 0.16 0.080742
hsa04920:Adipocytokine signaling pathway 6 0.14 0.048983
hsa05219:Bladder cancer 5 0.12 0.035633
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(oebiotech_11658, oebiotech_12721, oebiotech_21725 and
oebiotech_21831) had 8 cis genes, and the lncRNA with
the highest aberrant expression, lncRNA oebiotech_11933,
had 3 cis genes (C1orf74, G0S2 and TRAF3IP3). The aber-
rantly expressed lncRNA A_24_P927716 had 2 cis genesTable 3 GO analysis of lncRNA oebiotech_11933 co-expressio
Term
GO:0045449 ~ regulation of transcription
GO:0051252 ~ regulation of RNA metabolic process
GO:0006350 ~ transcription
GO:0006355 ~ regulation of transcription, DNA-dependent
GO:0007166 ~ cell surface receptor linked signal transduction
GO:0007242 ~ intracellular signaling cascade
GO:0006955 ~ immune response
GO:0042127 ~ regulation of cell proliferation
GO:0006952 ~ defense response
GO:0009611 ~ response to wounding
GO:0010033 ~ response to organic substance
GO:0016265 ~ death
GO:0008219 ~ cell death
GO:0031328 ~ positive regulation of cellular biosynthetic process
GO:0009891 ~ positive regulation of biosynthetic process
GO:0006915 ~ apoptosis
GO:0012501 ~ programmed cell death
GO:0010604 ~ positive regulation of macromolecule metabolic process
GO:0051173 ~ positive regulation of nitrogen compound metabolic process
GO:0042981 ~ regulation of apoptosis(ACSL1 and LOC731424). In MG patients without thym-
oma versus healthy controls, 36 lncRNAs had 127 ‘cis’
genes upstream or downstream of their chromosomal
position: lncRNA oebiotech_22652 had the highest
number of ‘cis’ genes and the aberrantly expressed
lncRNA oebiotech_11933 had 3 ‘cis’ genes (C1orf74,
G0S2, and TRAF3IP3). The lncRNA oebiotech_03926
had 2 ‘cis’ genes (BAALC and AZIN1). In MG patients
with versus without thymoma, 58 lncRNAs had 271 ‘cis’
genes upstream or downstream of their chromosomal pos-
ition: lncRNA oebiotech_22652 had the highest number of
‘cis’ genes, whereas lncRNA oebiotech_12244 had 6 ‘cis’
genes(PPBP, CXCL1, CXCL5, PF4V1, PF4, and C14orf45).






















Figure 2 The top 100 and top 200 GO terms or pathways for the difference lncRNA co-expression genes between the three groups.
A-B: The top 100 and top 200 GO terms or pathways for the difference lncRNAs co-expression genes between MG patients with thymoma
and healthy controls. C-D: The top 100 and top 200 GO terms or pathways for the difference lncRNA co-expression genes between MG patients
without thymoma and healthy controls. E-F: The top 100 and top 200 GO terms or pathways for the difference lncRNA co-expression genes between
MG patients with thymoma and MG patients without thymoma.
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oebiotech_21831, oebiotech_11933, and oebiotech_22652)
are shown in Figure 4. According to the ‘cis’ transcrip-
tional regulation mechanism, the genes that regulate tran-
scription in ‘cis’ are affected by other genes whose
chromosome positions are not far apart. Thus, the data
reduction strategy was used to overlay the genes located
upstream or downstream of the lncRNAs and the co-
expression genes.
The ‘trans’ mechanism of the aberrant lncRNAs and the
construction of the TF-lncRNA-target gene network
Currently, the known ‘trans’ regulation mechanism in-
volves the factors mediating chromatin regulation and
transcription. Using previously described methods
[32,33], we calculated the lncRNA co-expression genes
of chromatin regulators and transcription factors(TF) in
the Encyclopedia of DNA Elements(ENCODE) [34] toidentify common genes involved in lncRNA regulation.
The “TF-lncRNA” two-element network was generated
using Cytoscape software. The “TF-lncRNA” network is
large and complex because numerous aberrant lncRNAs
are involved. Therefore, we selected the top 100 largest
relationships with the “TF-lncRNA” network to generate
a core network map (Additional file 5). Figure 5A shows
the “TF-lncRNA” core network map for MG patients
with thymoma versus healthy controls. The transcription
factor CTCF modulated the expression of 72 lncRNAs,
whereas the TF TAF1 modulated the expression of 24
lncRNAs, and the TF MYC modulated the expression of
4 lncRNAs. Figure 5B shows the “TF” core network map
for MG patients without thymoma versus healthy controls.
The transcription factor CTCF modulated the expression
of 60 lncRNAs, whereas the TF MYC modulated the ex-
pression of 9 lncRNAs. The “TF-lncRNA” core network
map for MG patients without thymoma versus MG
Figure 3 Validationof the differences in the lncRNAs. A-D: The 4 different lncRNAs for MG patients with thymoma compared with healthy
controls. lncRNA oebiotech_11933 was the most elevated (19.96-fold higher), followed by lncRNA A_24_P927716 (14.75-fold higher), whereas
lncRNA A_21_P0010030 and lncRNA A_21_P0002844 were 3.94- and 6.43-fold lower, respectively. All differences were significant. E-H: The 4
differences in lncRNAs for MG patients without thymoma compared with healthy controls. lncRNA oebiotech_11933 and lncRNA
oebiotech_03926 were 5.45- and 33.1-fold higher, respectively, whereas lncRNA oebiotech_02627 and lncRNA oebiotech_22482 were 3.68-and
6.85-fold lower, respectively; all P-values < 0.05. I-L:The 4 differences in lncRNAs for MG patients with thymoma compared with MG patients without
thymoma. lncRNA A_19_P00315959 and lncRNA oebiotech_13222 were 6.99- and 6.46-fold higher, respectively, whereas lncRNA oebiotech_22652 and
lncRNA oebiotech_16223 were 4.58-and 4.08-fold lower, respectively; all P-values < 0.05.
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the expression of 8 lncRNAs (Figure 5C). The transcrip-
tion factor CTCF modulated the expression of 63lncRNAs, the TF TAF1 modulated the expression of 26
lncRNAs, and the TF MYC modulated the expression of
11 lncRNAs. These three maps provide a vivid picture of
Figure 4 (See legend on next page.)
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Figure 4 Representative lncRNAs and the positions of their ‘cis’ genes in the chromosome. The X abscissa represents the chromosome
genome position, and the Y coordinate represents the correlation coefficient of the lncRNAs and the ‘cis’ genes, with a greater correlation
coefficient corresponding to a higher position. The red line (or points) indicates the lncRNA genome width, and numbers in parentheses indicate
the length. The blue line (or points) indicates the location of the encoding genes; rho values for the encoding genes and lncRNA expression
correlation coefficients between the values, as well as the P-values for the correlation coefficients are shown. A-E: The results for the lncRNAs
oebiotech_11658, oebiotech_12721, oebiotech_21831, oebiotech_11933, and oebiotech_22652, respectively, are shown.
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factors and generate additional information for future
studies.
Based on the results of the lncRNA co-expression ana-
lysis, we added the target genes into the “TF-lncRNA”
network to determine the “TF-lncRNA-target genes”
three-element network relationship. The networks were
large and complex; therefore, we selected the top 300
relationships among lncRNAs, TFs and target genes
to produce the core network map (Additional file 6).
Figure 6A shows the core TF-lncRNA-target gene rela-
tionship for MG patients with thymoma versus healthy
controls, containing 8 lncRNAs with disrupted expres-
sion (lncRNAs oebiotech_24272, oebiotech_23755,
oebiotech_18319, oebiotech_13727, oebiotech_08281,
A_21_P0008564, A_21_P0006010 and A_21_P0001906),
27 target genes and 1 core TF CTCF in this core map.
Figure 6B shows the core TF-lncRNA-target gene rela-
tionship in MG patients without thymoma versus




oebiotech_00144 and A_21_P0007083), 41 target genes
and 1 core TF CTCF in this core map. Figure 6C shows
the core TF-lncRNA-target gene relationship in MG
patients with thymoma versus MG patients without
thymoma, containing 8 lncRNA with disrupted expres-
sion (lncRNAs oebiotech_22642, oebiotech_18319,
oebiotech_18319, oebiotech_09353, oebiotech_06898,
oebiotech_00715, A_21_P0010245, and A_21_P0009360),
27 target genes and1 core TF CTCF in this core map. The
relationship among these three elements could be visual-
ized using these three maps. Similar to the results shown
in Figure 6A, the only core TF CTCF association regulated
the expression of 8 lncRNAs and 27 target genes. The
8 lncRNAs might also regulate the expression of the 27
target genes. As observed for “CTCF-lncRNA oebio-
tech_24272-SOST” in this map, target genes, such as
SOST, were co-expression genes for lncRNA oebio-
tech_24272. The transcription factor CTCF may regulate
the expression of lncRNA oebiotech_24272and target
genes, such as SOST. Thus, these maps provided valuable
information concerning transcription factors, lncRNAs
and target genes.Discussion
The thymus plays a distinct role in the pathogenesis of
different MG subtypes. Marx et al. [10] divided MG into
subgroups (early onset MG, late onset MG, and
thymoma-associated MG) based on age of disease onset,
gender and genetic biases, antibody specificities and as-
sociated thymus pathologies. However, in the present
study, we divided MG patients into two groups: MG
with or without thymoma. The first aim was to identify
lncRNA subgroups as biomarkers to distinguish MG pa-
tients with or without thymoma from healthy individ-
uals. As shown in Table 1 and Figure 2, numerous
lncRNA subgroups were identified, providing the first
evidence of the involvement of lncRNAs in MG. We se-
lected 12 lncRNAs (lncRNA oebiotech_11933, lncRNA
A_24_P927716, lncRNA A_21_P0010030, lncRNA
A_21_P0002844, lncRNA oebiotech_11933, lncRNA
oebiotech_02627, lncRNA oebiotech_22482, lncRNA
A_19_P00315959, lncRNA oebiotech_13222, lncRNA
oebiotech_22652, and lncRNA oebiotech_16223) for fur-
ther validation among the 34 MG patients with or with-
out thymoma. In addition, we identified 42 upregulated
and 93 downregulated lncRNAs and 80 upregulated and
43 downregulated mRNAs (Figure 1D and Additional
file 2) exhibiting similar expression patterns, suggesting
that these lncRNAs and mRNAs are potential bio-
markers for the diagnosis of MG. Thus, the identifica-
tion of a subset of aberrant lncRNAs and mRNAs is the
first highlight of the present study.
Precisely annotating the functions of lncRNAs remains
complex. Here, we interpret the lncRNA functions based
on co-expression gene GO and pathway analyses. As
shown in Table 4), lncRNA oebiotech_11933is associated
with the MAPK signaling pathway, chemokine signaling
pathway, cytokine-cytokine receptor interaction, NOD-
like receptor signaling pathway, Toll-like receptor signal-
ing pathway, and adipocytokine-signaling pathway.
Colombara et al. [35] reported that the constitutive acti-
vation of p38 and ERK1/2 MAPKs in the epithelial cells
of a myasthenic thymus leads to IL-6 and RANTES over-
expression. Cytokines and chemokines regulate immune
responses in inflammatory diseases. Naïve CD4+cells
differentiate into T helper type(Th1, Th2, Th9, Th17,
and Th22) or regulatory T cells (Treg) through the ex-
pression of cytokines and chemokines. Because of the
Figure 5 The “TF-lncRNA” two-element networks for the three groups. A: The “TF-lncRNA” network between the MG with thymoma and
healthy groups. B: The “TF-lncRNA” network between the MG without thymoma and healthy groups. C: The “TF-lncRNA” network between the
MG with thymoma and MG without thymoma groups.
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Figure 6 The “TF–lncRNA-gene” core network map for the three groups. A: The“TF–lncRNA-gene” core network of the disturbed lncRNA
expression in MG patients with thymoma versus healthy controls. B: the “TF-lncRNA-gene” core network of the disturbed lncRNA expression in
MG patients without thymoma versus healthy controls. C: The “TF-lncRNA-gene” core network of the disturbed lncRNA expression in MG patients
with thymoma versus MG patients without thymoma.
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molecules with other cells, cytokines and chemokines
are likely important in the pathogenesis of MG. Cufi et
al [30] conducted RT-PCR analyses demonstrating large
increases in the expression of interferon (IFN)-I sub-
types (IFN-α2, IFN-α8, IFN-ϖ and IFN-β) in thymoma-associated MG, but not in MG patients without thym-
oma in control thymuses, and the abnormal regulation
of dsRNA-sensing molecules, with the increased ex-
pression of Toll-like receptor 3 (TLR3) and decreased
expression of protein kinase R (PKR) and dsRNA heli-
cases (RIG-I and MDA5) in MG patients with
Luo et al. BMC Medical Genomics  (2015) 8:13 Page 12 of 16thymoma. These authors suggested that INF-I overex-
pression and the activation of innate immunity path-
ways in thymoma-associated MG may develop after a
pathogen infection. Cufi et al [27,29] also observed the
contribution of IFN-I and IFN-III subtypes in thymic
changes associated with MG. The IFN-I and IFN-III
subtypes, particularly IFN-β, specifically induce α-
AChR expression in thymic epithelial cells (TECs), and
IFN-β increases TEC death and the uptake of TEC pro-
teins in dendritic cells. In parallel, these results showed
that IFN-β increased the expression of the chemokines
CXCL13 and CCL21 in TECs and lymphatic endothelial
cells, and similar results were obtained in C57BL/6
mice. All of these studies were performed using thymus
tissues. In the present study, our aim was to identify
potential biomarkers for the diagnosis of MG; there-
fore, we performed our studies on PBMCs. We identi-
fied several cytokine and chemokine GO terms and
pathways that are consistent with the aforementioned
studies. It is reported that the cytokines/chemokines in
PBMCs may originate from the thymus [7,10]. Uzawa
et al. [36] measured the serum levels of 27 cytokines/
chemokines in 47 anti-acetylcholine receptor antibody-
positive patients with MG and 20 healthy controls to
investigate the contribution of cytokines/chemokines in
MG pathogenesis. These authors identified eight cyto-
kines that were significantly changed among MG pa-
tients with thymoma (i.e., IL-4, IL-8, IL-15, eotaxin,
macrophage inflammatory protein-1α, macrophage in-
flammatory protein-1β, VEGF and IL-1b). Cordiglieri
et al. [37] reported that TLR4 stimulation in MG TECs
increased CCL17 and CCL22 expression and induced
the production of Th17-related cytokines. TLR4 signal-
ing in the MG thymic milieu might affect cell-to-cell
interactions, favoring autoreactive T-cell activation.
These results and the results obtained in the present
study suggest that lncRNA oebiotech_11933 could play
an important role in the pathogenesis of MG.
The most enriched GO terms in the predicted target
genes of the lncRNAs were ‘cell response to interferon-γ’,
‘platelet degranulation’, ‘chemokine receptor binding’ and
‘cytokine-cytokine interaction’ in the pathogenesis be-
tween MG patients with thymoma and MG patients
without thymoma (Figure 3). Many studies have shown
that the number of immune cells secreting IL-2, IL-4,
IFN-γ, and IL-10 are significantly higher in patients with
MG than in healthy individuals [38-40]. The results of
the present study demonstrated that the most important
GO term was ‘cell response to interferon-γ’, suggesting
that aberrant lncRNAs may play an important role in
regulating IFN-γ expression. Interferon γ is a soluble
cytokine and a member of the type II interferon family
with antiviral, immunoregulatory and anti-tumor prop-
erties as a potent activator of macrophages. Tuzun et al.[41] reported that MG patients with low plasma IL-6
and IFN-γ levels attained better clinical improvement
following etanercept treatment. An increasing number
of studies have shown that IFN-γ regulates T and B cell
differentiation [42-44]. The GO and KEGG pathway ana-
lysis of lncRNA co-expression genes to determine the
functions of lncRNAs is the second highlight in the
present study.
The molecular regulation through lncRNAs remains un-
known because the functions of lncRNAs vary [32]. In-
deed, lncRNAs have been identified using a variety of
methods, and the number of specific lncRNAs shown to
influence genomic functions, including roles in imprinting
[45], enhancer functions [46,47], X chromosome inactiva-
tion [48], chromatin structure [49] and genomic rear-
rangements during the generation of antibody diversity
[50], is increasing. Here, we utilized the ‘cis’ versus ‘trans’
regulatory mechanisms to obtain additional information
on dysregulated lncRNAs. In the present study, we ex-
plored ‘cis’ regulatory relationships (Additional file 4). The
outstanding lncRNAs are shown in Figure 4. The in-
creased expression of cytokines and chemokines, such as
IL-8, CXCL1, CXCL3, CXCL3, and CXCL5, was observed
among the oebiotech_11658, oebiotech_12721, oebio-
tech_21831, oebiotech_11933, and oebiotech_22652 ‘cis’
genes, suggesting that these lncRNAs may regulate the ex-
pression of these cytokines and chemokines. The results
of this ‘cis’ analysis provide additional information con-
cerning the regulation mediated through lncRNAs and
the biological processes in the pathogenesis of MG. We
constructed the “TF-lncRNA” and “TF-lncRNA-target
gene” network based on the results of the ‘trans’ analysis
(Additional file 6). The core TF-lncRNA-target gene net-
work (Figures 5 and 6) showed that TFs, including CTCF,
TAF1and MYC, regulate lncRNA expression in MG. The
CTCF gene is a member of the BORIS + CTCF gene
family, encoding a transcriptional regulator protein
with 11 highly conserved zinc finger (ZF) domains.
This nuclear protein uses different combinations of the
ZF domains to bind different DNA target sequences
and proteins. Depending on the context of the site, this
protein binds to the histone acetyltransferase (HAT)-
containing complex and functions as a transcriptional
activator or binds to the histone deacetylase (HDAC)-con-
taining complex and functions as a transcriptional repres-
sor. When the protein is bound to a transcriptional
insulator element, the communication between enhancers
and upstream promoters is blocked, thereby regulating
imprinted expression [51,52]. Thus, the ‘trans’ analysis pro-
vides another method to interpret lncRNA function and
the biological processes in the pathogenesis of MG. The
results of the ‘cis’ and ‘trans’ analyses provide information
concerning the modular regulation of lncRNAs, represent-
ing the third highlight of the present study.
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In the present study, we identified a subset of aberrant
lncRNAs to distinguish MG patients with or without
thymoma compared with healthy individuals. The function
and biological processes of lncRNAs in the pathogenesis
of MG were determined according to co-expression gene
GO and pathway annotations. The results of the ‘cis’ and
‘trans’ analyses provide information for future studies of
aberrantly expressed lncRNAs in MG. These results
provide support for future investigations of the patho-
genesis of MG.
Method
Patients and sample collection
MG Patient Demographics
A total of 34 MG patients examined at the Neurology
Department of Xiangya Hospital and 13 healthy donors
were recruited from May 2010 to March 2012. MG was
diagnosed based on a combination of fluctuating muscle
weakness with a positive neostigmine test or abnormal
single-fiber EMG test. The MG patients were divided
into two groups: patients with or without thymoma. The
Myasthenia Gravis Foundation of America (MGFA)
clinical classification was also used to identify MG sub-
groups. All MG patients did not receive immunomodu-
latory or immunosuppressive treatment and were not
treated with thymectomy. Information pertaining to
sex, age at onset, disease duration, MGFA clinical clas-
sification upon first visit to the hospital, additional
autoimmune diseases, including thyroid disorders, sys-
temic lupus erythematosus (SLE), rheumatoid arthritis,
and Sjogren syndrome, and previous treatments, including
acetylcholinesterase inhibitors, immunosuppressive drugs,
prednisone, plasma exchange, IVIg and thymectomy, is
summarized in Additional file 7. The samples MG1-8 and
Normal1-4 were selected for lncRNA chip analysis, and
all of the samples in Additional file 7 were used for the
validation of lncRNA expression. All patients and
healthy volunteers provided informed consent for sample
collection and have signed informed consent forms.
Collections and use of tissue samples were approved by
the Ethical Review Committee of Xiangya Hospital. The
PBMCs were isolated from approximately 10 ml of
EDTA whole blood using a Ficoll-Paque™ PLUS density
gradient, and then, 5x107 cells were resuspended in
Trizol® (Invitrogen) and stored at -80°C.This study was
approved by the ethical review committees of Xiangya
Hospital.
RNA extract and the lncRNA chip array
lncRNA microarrays
Total RNA was extracted from PBMCs using Trizol® re-
agent (Invitrogen). Approximately 200 ng of total RNA
from each sample was used for the lncRNA microarrayanalysis. lncRNA expression was analyzed from May
2012 to August 2013 using OE_Biotech Human lncRNA
chip software V2.0(4*180K),containing 46,506 lncRNAs
and 30,656 mRNAs collected from eight authoritative
databases, including Agilent_ncRNA, lncRNAdb, Gencode
V13, H-invDB, NONCODE v3.0, RefSeq, UCR and
UCSC_lncRNAs Transcripts. The lncRNA chip experi-
ments were conducted at the OEbiotech Corporation in
Shanghai, P.R. China.
Bioinformatics analysis
Difference lncRNAs and mRNA screen
Raw data from each array were first normalized using
GeneSpring software (version 12.5) and subsequently an-
alyzed using an unpaired t-test, with a P-value cut-off of
0.05 and a fold-change cut-off of 2.0.
Difference integration analysis (Venn analysis)
MG patients with or without thymoma were compared
with each other and healthy controls. The common
characteristic elements between the three groups were
determined using Venn analysis.
Difference lncRNA and mRNA clustering analysis
Different lncRNAs and mRNAs were analyzed using
Cluster 3.0 software, and the data were used to examine
a series of parameters, such as log transform data, nor-
malized genes and arrays, and hierarchical parameters of
genes and arrays. The results were further analyzed
using Tree View software. Green-yellow indicates low
expression, and red indicates high expression.
lncRNA co-expression analysis and gene function
annotation
The expression of different lncRNAs and mRNAs was
analyzed using Pearson’s correlation coefficient. The
absolute value of 0.8 was considered relevant, a value
less than 0.8 represented a negative correlation, and a
value greater than 0.8 represented a positive correlation. A
P-value of less than 0.05 was considered statistically sig-
nificant. The expression of genes encoding each differen-
tially expressed lncRNA, the ontology classification of the
co-expression genes based on gene annotation and sum-
mary information are available through DAVID (Database
for Annotation, Visualization and Integrated Discovery).
The predicted target genes were assigned to functional
groups based on molecular function, biological processes
and specific pathways. The lncRNA gene function was
predicted based on the co-expression gene GO functional
annotation, selecting (according to the P-value) the top
100 GO and 200 function reliability prediction terms. Stat-
istical function annotation generated additional GO terms,
and the most enriched terms might reflect potential
lncRNA functions.
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The gene location for different lncRNAs on the chromo-
some was determined. Subsequently, the common
lncRNA co-expression genes were intersected to identify
the genes 300 kbp upstream or downstream of the
lncRNAs as potential ‘cis’ genes. The schematic shows
the chromosome location of the lncRNAs and cis genes.
TF-lncRNA network
lncRNA sequences were mapped to the genome in the
Sanger database. Jemboss software was used to examine
the alignment of lncRNA and putative transcription factor
binding sequences. The genome browser database was
used to build the network describing the relationships be-
tween transcription factors and lncRNAs. An adjacency
matrix was implemented in Java according to the binding
of lncRNA and transcription factors. The core transcrip-
tion factor is the most important center in the network,
with the highest degree of expression [53,54]. Pearson’s
correlation analysis [53] was used to measure the regu-
latory ability of transcription factors by calculating the
correlation between transcription factors and lncRNAs.
The TF and lncRNA relationship was generated using
Cytoscape software. The red circle indicates the
enriched lncRNAs or TFs, and the larger size indicates
increasing enrichment.
TF-lncRNA-gene network
The TF-lncRNA-gene network was constructed based
on the interactions of lncRNAs and target co-expression
genes as previously described [55]. The lncRNA co-
expression genes and the compounds for chromatin
regulation and transcription complexes were intersection
elements. Intersection elements might participate in
lncRNA-mediated gene regulation. The three groups
were generated using Cytoscape software based on the
“TF-lncRNA” two-element network. Because many
lncRNAs are involved, the “TF-lncRNA” network is difficult
and complex. Therefore, we selected the top100 closest as-
sociations with the “TF-lncRNA” network to produce the
core network map.
Quantitative reverse transcription–polymerase chain
reaction analysis
Total RNA was extracted using Trizol® reagent (Invitro-
gen). The primers for RT-PCR were designed based on the
lncRNA sequences from the UCSC. The primers were syn-
thesized and purified at Invitrogen (Shanghai, China). The
RT reactions were performed using a cDNA synthesis kit
(Bio-Rad, Hercules, CA). Real-time PCR was performed
using the ABI StepOne Plus™ Multicolor. The qPCR cycle
was 98°C for 2 min, followed by 40 cycles of 95°C for 15
sec and 60°C for 30 sec. A final melt-curve analysis (60–
95°C) was included. The standard curve was produced withslopes at approximately -3.32 (~100% efficiency). The
lncRNA PCR results were quantified using the 2ΔΔct
method against GAPDH for normalization. The data
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